Stocks Health care SVA
NASDAQ · Health careSinovac Biotech Ltd (SVA)
Sinovac Biotech Ltd reported revenue of $386M in fiscal 2025, up 6.8% from a year earlier. It posted a net loss of $59.7M. In fiscal 2025 capital spending exceeded operating cash flow by $561.1M. At December 31, 2025 it held $488.2M in cash against $494.9M of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on June 5, 2026.
What Sinovac Biotech Ltd does
Sinovac Biotech Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SVA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $386M | -$59.7M | -$0.83 | -$561.1M |
| 2024 | $361.4M | $90.9M | $1.27 | -$152.9M |
| 2023 | $470.2M | -$13.5M | -$0.19 | -$17.5M |
| 2022 | $1.5B | $14.5M | $0.20 | -$1.1B |
| 2021 | $19.4B | $8.1B | $113.44 | $14.7B |
| 2020 | $510.6M | $110.4M | $1.48 | $351.8M |
Full financial statements: income, balance sheet and cash flow
Where SVA ranks in Health care
Dividends
Sinovac Biotech Ltd declared $55.00 per share in fiscal 2025. It paid out $3.5B in cash dividends.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $55.00 | $3.5B | n/a |
| 2024 | n/a | $947M | 1,042% |
| 2023 | n/a | $328.1M | n/a |
| 2022 | n/a | $247.4M | 1,710% |
| 2021 | n/a | $1.9B | 23% |
| 2020 | n/a | $0 | 0% |
Latest SEC filings
What Sinovac Biotech Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 17, 2026
- July 15, 2026
- June 15, 2026
- June 5, 2026
- June 5, 2026Annual report (foreign issuer) 20-F · period to December 31, 2025Revenue rose 6.8% to $386M versus the prior year; diluted EPS -$0.83 versus $1.27.
- May 29, 2026
- May 21, 2026
- May 8, 2026
- May 7, 2026
- April 30, 2026Form NT 20-F filing NT 20-F
Questions about SVA
What does Sinovac Biotech Ltd do?
Sinovac Biotech Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SVA.
Is Sinovac Biotech Ltd profitable?
No. In fiscal 2025 it reported a net loss of $59.7M on revenue of $386M.
How much revenue does Sinovac Biotech Ltd make?
In fiscal 2025 Sinovac Biotech Ltd reported revenue of $386M. That is 6.8% more than a year earlier.
When did Sinovac Biotech Ltd last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on June 5, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from August 17, 2026.
Similar companies
Compare SVA with
Follow SVA
Get an email when Sinovac Biotech Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Follow SVA: get an email when it filesWhere the numbers come from
Financial figures are the values Sinovac Biotech Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.